Rivaroxaban versus usual care for fast, frequent heart beats
Part of Heart & circulation clinical trials.
This study tests whether rivaroxaban (a blood thinner) is better than standard care for people who have very frequent early heart signals (atrial ectopy/short runs) and a higher risk of stroke. It also checks whether treatment affects bleeding risk and brain changes seen on MRI over 24 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 65 or older
- Your 24-hour heart monitor (Holter) showed either at least 1% abnormal atrial signals (PACs) or short runs with at least 20 PACs
- Your stroke risk score is high (CHA2DS2-VASc score of 3 or higher)
- You can attend study visits and get a brain MRI at the start and again at 24 months
- You can understand the plan and follow instructions, and you agree in writing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two doses of rivaroxaban (15mg and 20mg) to see how well they prevent strokes in people with non-valvular atrial fibrillation, a type of irregular heartbeat not caused by a heart valve problem. It may be an option if you need blood thinners to lower your stroke risk.
This trial tests if a full dose of rivaroxaban (a blood thinner) works better than a lower preventive dose for treating a superficial vein clot in the leg. It aims to find the safest and most effective way to stop the clot from getting worse or causing a more serious clot.
This trial tests whether a lower dose of the blood thinner rivaroxaban works as well as the standard dose for people 70 and older with atrial fibrillation (an irregular heartbeat). The goal is to find the safest dose to prevent strokes while reducing bleeding risks.
This trial tests a blood thinner called rivaroxaban (Xarelto) given right after heart valve surgery with a tissue valve. It aims to see if it can prevent blood clots or strokes safely in the early recovery period.
This study compares two commonly used blood thinners (apixaban and rivaroxaban) to see which works better for people with non-valvular atrial fibrillation, a type of irregular heartbeat. The goal is to find the safest and most effective option for preventing strokes.
This study compares two common blood thinners, apixaban and rivaroxaban, in veterans with atrial fibrillation or flutter to see which one is safer and works better. If you are already taking one of these medicines, you may be able to join.
Hear when a new Excessive Supraventricular Ectopies or Short Atrial Runs (ESVEA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.